Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-03-29
2005-03-29
Kim, Vickie (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S642000, C514S624000, C514S634000, C514S231200, C514S509000, C514S565000
Reexamination Certificate
active
06872751
ABSTRACT:
The present invention relates to methods for prevention and/or treatment of diseases or conditions caused by deficiency in the adult isoform of a given protein wherein said method comprises administering to a patient in need thereof a composition containing NO or at least one compound able to release, induce and/or promote NO formation in cells, said administration resulting in augmenting or restoring the production of the fetal isoform of said protein in said patient.
REFERENCES:
patent: 5789447 (1998-08-01), Wink et al.
patent: 5885621 (1999-03-01), Head et al.
patent: 6153186 (2000-11-01), Stamler et al.
patent: 29709820 (1997-07-01), None
patent: 0 870 763 (1998-10-01), None
patent: WO 9528377 (1995-10-01), None
patent: WO 9602241 (1996-02-01), None
patent: WO 9710265 (1997-03-01), None
patent: WO 9725984 (1997-07-01), None
patent: WO 9733173 (1997-09-01), None
patent: WO 9737644 (1997-10-01), None
patent: WO 9813358 (1998-04-01), None
patent: WO 9901427 (1999-01-01), None
patent: WO 0053191 (2000-09-01), None
Kameya et al., The Journal of Biological Chemistry, 1999, vol. 274, No. 4, Issue of Jan. 22, pp. 2193-2200.*
“New Hope for people with Sickle Cell Anemia”, Eleanor Mayfield, FDA Consumer, May 1996.*
“Sickle Cell Anemia”, National Heart, Lung and Blood Institute, 1996.*
“Duchenne Muscular Dystrophies-Annual Condition Specific Review”, Muscular Dystrophy Campaign, Sep. 2001.*
“Thalassemia-What is Thalassemia?”, University of Rochester Medical Center, 2003.*
Shuichi Yamada: “Effects on ATP and amino acid mixtures on progressive muscular dystrophy,” Sapporo Igaku Zasshi, 1965, pp. 284-297, vol. 27, XP002131218.
D.S. Bredt, “Endogenous nitric oxide synthesis: Biological functions and pathophysiology,” Free Radical Research, 1999, pp. 577-596, 31/6, XP00213219.
J.W. Haycock et al., “Oxidative damage to muscle protein in Duchenne muscular dystrophy,” Neuroreport, 1996, pp. 357-361, vol. 8, No. 1, Rapid Science Publishers, XP000879014.
D.S. Chao et al.: “Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy,” J. Exp. Med., 1996, pp. 609-618, vol. 184(2), The Rockefeller University Press, USA.
R. Lainé et al.: “Neuronal nitric oxide synthase isoforms.alpha.and.mu. are closely related calpain-sensitive proteins,” Mol. Pharmacol., 1998, pp. 305-312, vol. 54(2), The American Society for Pharmacology and Experimental Therapeutics, USA.
A. Decrouy et al.: “Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4cv skeletal muscle fibers,” Gene Therapy, 1998, pp. 59-64, vol. 5(1), Stockton Press, United Kingdom.
G.B. Azzena et al.: “Nitric oxide regenerates the normal colonic peristaltic activity in mdx dystrophic mouse,” Neuroscience Letters, 1999, pp. 9-12, vol. 261, Elsevier Science Ireland Ltd., Ireland.
G.D. Thomas et al.: “Impaired metabolic modulation of alpha-adrenergic . . . ,” Proc. Natl. Acad. Sci. USA, 1998, pp. 15090-15095, vol. 95/25, The National Academy of Sciences, USA.
E. Chaubourt et al.: “Nitric oxide and L-arginine cause an accumulation of utrophin at the . . . ” Neurobiology of Disease, 1999, pp. 499-507, vol. 6/6, Academic Press, USA.
W.H. Waugh et al.: “Evidence that L-arginine is a key amino acid in sickle cell anemia- . . . ”, Nutr. Res. (N.Y.), 1999, pp. 501-508, vol. 19(4), Elsevier Science Inc., USA.
A.N. Schechter: “NO Therapy?,” Journal of Clin. Investigation, 1997, pp. 955-956, vol. 100/5, USA.
C.A. Head et al.: “Low concentrations of nitric oxide increase oxygen affinity . . . ”, J. Clin. Invest., 1997, pp. 1193-1198, vol. 100(5), The American Society for Clinical Investigation, Inc., USA.
S.P. Perrine et al.: “Butyrate-induced reactivation of the fetal globin genes . . . ”, Experientia, Birkhäuser Verlag, 1993, pp. 133-137, vol. 49, No. 2, CH-4010, Basel/Switzerland.
R. Pacelli et al.: “Hydroxyurea reacts with heme proteins to generate nitric oxide,” Lancet, 1996, p. 900, 347/9005.
C. Morris et al.: “Effects of L-arginine therapy on nitric oxide production in patients . . . ”, Blood, (Nov. 15, 1998), p. 2858, vol. 92, No. 10, Suppl. 1 Part 1-2, Lippincott Williams & Wilkins, USA.
C.O. Enwonwu: “Increased metabolic demand for arginine in sickle cell anemia,” Med. Sci. Res., 1989, pp. 997-998, vol. 17(23).
G.D. Sher et al.: “Extended therapy with intravenous arginine butyrate in patients with beta . . . ”, New Eng. J. of Med., 1995, pp. 1606-1610, vol. 332/24, Massachusetts Medical Society, USA.
C.R. Morris et al.: “L-arginine therapy paradoxically decreases nitric oxide production in patients with sickle cell disease,” Ped. Res., 1999, p. 876, vol. 45, No. 4, Part 2.
A.M. Atz et al.: “Inhaled nitric oxide in sickle cell disease with acute chest syndrome,” Anesthesiology, 1997, pp. 988-990, vol. 87, No. 4, Lippincott-Raven Publishers, USA.
Baux Gérard
Chaubourt Emmanuel
De La Porte Sabine
Fossier Philippe
Israël Maurice
Burns Doane , Swecker, Mathis LLP
Centre National de la Recherche Scientifique "CNRS"
Kim Vickie
Kwon Brian-Yong S.
LandOfFree
Composition and method for augmenting or restoring the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for augmenting or restoring the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for augmenting or restoring the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375112